Kyntra Bio, Inc. (KYNB) Stock Analysis & Investment Frameworks
Kyntra Bio, Inc. (KYNB) stock analysis on Invetso. Review Kyntra Bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Kyntra Bio, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Kyntra Bio, Inc. Key Financial Metrics
- Market Cap: $19.64M
- Revenue: $6.44M
- P/E Ratio: 0.11
- ROE: -605.53%
- ROIC: -78.16%
- Dividend Yield: N/A
About Kyntra Bio, Inc.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Kyntra Bio, Inc. Investment Frameworks
Invetso analyzes Kyntra Bio, Inc. (KYNB) across the following frameworks:
- Kyntra Bio, Inc. 10Y Growth Potential
- Kyntra Bio, Inc. Scenario Analysis
- Kyntra Bio, Inc. Risks & Opportunities
- Kyntra Bio, Inc. Economic Moat
- Kyntra Bio, Inc. Business Model
- Kyntra Bio, Inc. Management
- Kyntra Bio, Inc. SWOT Analysis
- Kyntra Bio, Inc. Porter's 5 Forces
- Kyntra Bio, Inc. PESTLE Analysis
- Kyntra Bio, Inc. ESG Analysis